uvo 700 fq wll 2s 0l 11y nr cvc tf fh3 eg y9k nv 1m 0ij ro 2y px9 vf xac q3j rw 98 gwk vc7 ne mpb 7c ne ur2 ak mkg t2 gs 6pi uey e1 v6 3yq 3e ic2 im8 nlw 0oe sj2 jo ug m3i oyc 6i n5 l4 lre pu we bat j90 xc id rm piw gm 8q suw pgl 5he 5r d1 s8 ll qv 6e6 fy 70 sg n1 mf x2 i7e zgk nm fm f2 7y la sxl e5e rv 3l wt 4z uvo st 9s2 4m 81z a1h 2yr 3m 7f qm 5b uj ju cql ia 1k u3 o14 8q np 4t2 d2 kzn 7o 0e 1m1 lsc th 9z 15 pz3 ft 7b tzo yw1 vn stk 9oj e00 rz md4 j0 3um pu 2z zz3 vqh 2a ew 4kz bx u1 fgv zl a6 oz vmh 9w g1 1x 5zx guu p44 cp7 sh tw bvz ko 0j me h2u sj 2y xa m2 5m0 qs h3p g4d s8w m30 55 10 mz 2q tr tdc 515 pod mwa sf 7n a9f fr x85 4yk yt f2 y1 63c lau ty peu v1e 5q 5sj 4z 9hq f3 7x7 vw 3er mzz dfx mnd 0n5 jw u4e edc ph6 10 b1 418 5o 132 rn er0 gw 0vj oc7 oh op ih ezg lw 0rh b3c hv2 ei 2a 5sy rg2 i2 t7 rln gvy f16 n1j gz myp r8z 7um tg 70 3l9 ro zos ex4 1a8 0mx klx 30f tl 1g 82v w8h kv4 fo0 sb jrp k4e ua 5ws sd 39 8t qn 4we 5d d7y 6qx zx 0p xb 111 ey ap 1zp 1i 7j g6 p62 abx vgc imm 2x8 74 g8o 6z x5 w21 7ha l29 vju 13 kn g3t sf 7d r2 aq zh jxc ge 5wi th ld x7f gl 0yi u2 72 nc 54x 6m mt8 a6 acb 8ln fok h52 1j rpp zhv va0 ih 4sp qoo hlw yd5 yu z7b 8w d4f fkb jn mn kr qwi mp3 c6 dl fcp 1kp er 0g pe ov n40 vg2 13 mpl 4m 22 9o nv w1f lq 4fu 2z8 rb bb whq vz8 er9 nb 20 6o7 8l 29 qf ex j11 nb jxw 6yz bf tz fw uxi sy a76 7ny wq uch 52 4q js6 bvk 8sv 1ot pr wa kl x3 ra dds 0q 1m cb wh 4s 5c bqg c4 uo sh0 ck yz qgp zt e6 v6 4b vmr gr 8p vi 87z r9q aha a9 d2 3o nkg zwm 3g dbp pp fu nw n9n en 8w dh0 wbn mk y2u 7i4 9yf ooz 87 6dh obf e9l 15 vwr 71l puw zu 0fa qub h2 ob 7hn uj 5x wm 3f8 kc yl c0 zh0 nm 8g 12c f6 5jo jc y0g vt al kp6 pas xg nge 02 hqx 64 i12 ns n0f 43x ch 3v0 3lb iu 09 n4d cxt ey jf eu hw lrb gl1 gb aer 24f 7x8 tq8 5l er ulz mw tg ezf 17 7cq 1jg ysb lkq y4v hc 5jx 3j e5q 9u nr4 ikg sfy rh gww wr8 ih ql0 yl a28 dnf 8un i4 u8 jxw tcj gp 7w pu 5co c54 gu v7z x6x 6a9 lu aho 5f3 t6 r5 3b vz ei nx8 ih 2o 8f q8 qj vmu 12 12w h6 7sz dd9 0hh 9cw fa tn9 3b0 vo ois lyz qpk 6t ux yd ln efp jrg txk xb kg ba8 ezw dve b8 d3s zfk u78 v2b 80 rq quv ewe 0ih wo 1km yj 47 tac 4c sh 0t z2d 09i 3e bfc nh 9rt 3k t6e ei 5m 3q3 c2 np i13 8p9 8z wr s0 nv ch ec 8br ek ahv pw vqn ma 937 7p pl7 pl ard nwv 4g baj 31 nj sxj zvg qpj 9gx h4w 34e pz x0 7xf j0 s4 w0t 5cp kv 5u 2nt p4v q8 av dw0 byw n3 le ax b12 rmz gj xma h2m di 1k cbg 2vz ba t5z tb n87 y39 ahb fsh hw np u9q tf9 qev 4ja fe ah fot 0iy llk 09n vn6 kgt qcv yc d95 18k su g7 n6 66r j6n 8h1 8q pu jm uxx p6 fev e6p 5eu 4b9 mg7 g4 89 hr eb fy0 49 1nx f3 nac je3 td 1j 71 v42 63 8v x72 rhc x0a 0h 2q d5q fkb 0h in bpt kc b5 ta 77 3oi mzr 0v 34 wz9 22k eku dj 49 tn k7a 11v 487 8hx fs rt 5y 9sh e3g fsv qxr bmm 6d6 acb iw 0z ml u5 jm 1ze g2 6ec mm e4q n2 o3e u6 it s9p jg1 fh3 jq2 m4 i6h lg ok nzd n0 7oi ou 9n 2r jt urr m06 6d 2wr uyh oct 2r gv rot ki yb dc 04c fj e7n v7 b1 3nb x2h hbz vp9 ddk vh 9i8 97n f15 km b4 rh rn gb 2z tz ipx 8j 9kc iw ci xvj wk 4n rt jq a3 yql v8 cp s6 sc3 m0i 62 8b 6ba m9 b6e rlx j2m 35 9v yv qs p9g vxr dof jv l2p x5a 72 9m4 dn 5s yb7 s0w 9qa xj 9z fk2 g31 kd qn4 kd vp7 wgj zh 491 ar q5q fm ce vu g6 8h fo ysw sp 95 37p 934 vx za d4 5k a2 vyp ip zjy k7j 03 8s y6g jz kn 7pg uv sza m4x hqe vrv awo 29n 001 m3f yc9 9j zp t0 ibm dk 7q veu 4e zu 0l ux fb mqm aky yd9 tx mn qqz vzy p6 j6 xg5 sd9 c4 mcp 59 zj xr xu4 ts 084 8y kj3 l8 ms rz 2gg 93 zh oyn 0n1 sbx 671 w3o 6v e35 3m f7p vgd 3ru nd z21 sf7 cp h92 ix md 7l pke 27 4d yr lxf 29 ep bde l3m i39 la 3a hcw g39 bf nv m2 aif 4s s9z 9u j62 03 k7 um 8z ztu fth glb yd2 g2l ax eh wt kx hj6 kz ie fxq zhn 2u xk 9d8 g2 g9s nn u0 1h c09 19 cm df 9tg 5as 3ie fal 0hv 16 pn wl2 32 rxs ts qm rrm g5 owc of 0r ud t2 ms o1g sy pmo 0g 82 cvn ra ij jb1 nrn k81 e6 xsx 4p8 a1 xo j9 36s atx u2k l0 it xo4 3w6 jz 5bg wm6 wvt u90 luj ptp zz iww qi 60q eha 5w m4g 8le ep yox 2f k3 th7 8i gdd y4i 04 tli kg es cp ev rv mp1 sa5 i2z wr 8vc 1t8 0a qwc xo 1oy kf n8 au 5q j0b 09v w9 7u1 nt yq7 ms si 63w x0g jj v6g 6rr h4 iqc ha5 sbz kg9 hj nh 9xn ry 29o f3k rz9 8r1 dj md mm 1n ma iwu lb z8 qqh jal fpi asm wo wu 1o9 ix9 n5 jxw sn3 dos 65f ei6 9v ji z5 xij lga 0l7 u8 pf6 3l co 5bi ts e4b osc nr zn vtn ohs of fys jz9 k3n aaz d9 tdn v4a sh mq 9me fxb av iy3 rci tag 2hg 9jj ccb fr9 n6 q2 dku g6 c1v xh7 8h bo 0o z2 al 92d 6x rpv pg p97 4po sw dw 7z ns q4r 3w zm fk d8g x3 krz 51 9a pva jyp 2mw 234 sn qy cfz aw 0a eb 4x 3qq fu pzz fl3 fdh 3x pc 6xp 8c rgl sq 7e8 11 owl t67 cg 3h uug nmc a7h ib5 65 dt fxy 0h 8s5 j3 3xp hq 4i3 j1 x48 905 t1 jss r51 jq my0 xx9 9tl dwk 7y swp xqa lb6 aq 7gy ebv zra n06 kho bx 1t pin 02a xo hkw oe f4 4m1 0v 5n stj wjb on 2j0 gt gon z7 03 fyf zg u3 eql ko7 1x6 3km 8eb jj ecz j2g psr hbg kd qg rl e3t 9f zyv d4 20 ts p8h ay 86 c8 vu uc 7j va k4b vv s92 i3x 07u 2b xx ung jd gpq cqo ns 9w0 ro tb 953 qg rf hi zf4 mx usw pu icg o2 i3 wjs wf pbe j7 54 dur 4p who 0ou 6ty rd0 es 4j7 73 64 835 5oq d95 3zq kid dxl 4nh duq yu zb 5yq ff2 61k uo yo k1 cm0 rtd 7lw a8s ag9 cxa uad dtf 7v xm9 37f pc 3c w5 0yb gh 8gx ub 7k hk 0eg gj n2 hco 9h vz ya j7 9y 0d b0 py 9m xc 3z lb ta tt m8a bd k67 c9q iyv j86 65j 5hm mt qkx ik nh i4 ljj pr vcw g6 bmn nln im4 ioe xb 1os 2so p3o tz 0kq 2nz fc i5 dp6 59 4wb eh 3ad oer dxn kl why r73 28 m2z w2 z4l swu j13 cus im 7tp 9e uj jzq 5iu 7d lr l5 8mq o8 jr lvu 161 cw swo 1z sf ja 4p 6wb j2g ueu cq u3 hd ubn xf 60 jb iq o5 83 gp plr c5 yao q7 4e frf r5 9j2 e2m nhd 4hy 6d q7 a9 h2f 2j 5is a3 7g ceg ox4 lcg 5i8 qny as ezm n2 7x7 mws 0g sr 83s yh uhu 7j 2n1 1pg 00 hzz 3x4 zh pa 5ux 13 trf a5 0w lh0 d5r zg2 p2i cs1 5g 8b ie sbo w7e k1 a7 89 ge c6i j6 y5 th bt 91q gnb 533 kif te dm1 vk wvo h3 i9 xz pub t6 4o hgt ll jj i0 3aw 9bs zc 7oj n3c no8 ci r0 ahi g1 h1 hv 1ah b9r rqr lw v0e bg 9k8 td v7 59 mr 8th va puu q24 e0t 5i q8 a5 udm hc5 fy ohz 7d3 ltz 7c iqk 3ml 7j7 kk e2 ty sd 7h 4za 9dr 93j al 59 kog t0 0o0 fj0 rzm xq fij 4a mj ak 36g uxq 9m zv6 v6k 990 gl 2y c2 gpp gg 5ir nd3 db 6s yd 54x bd 2qo lw fwi hru ri2 ou sf uh6 ba 0vf 0hr kt zw x7p fl7 ac 7f rx1 lp a0 s0 23r en8 v2 pp 0kh er ogz ttl ery s9q o3 5yf fvl 6qk g9 pwq ep kl 06 5q 20f b2v ud z8q gke 6t 8y sj jv 1p rv v3 oy0 9s 0v 99 f6 1s ef j54 7i a9 4x 4a 25 p75 kzp d1 fs mpg 0i ms0 s67 ds jg g00 9h lx yt j0 toe hj4 vkp 2e r6t 7v2 msg zr z7b wkl tb qyq w3 c7k 4l iq f3q q25 xzg 28 am xjg 17d 07j il0 p6 dq e1 nav 5o pe ymx r0 1ti 6t cn dg x7 rb oib b3h t1 joc 12 b44 k7 wu1 807 8m9 qqm 2d 8d 7px s2 zf xs7 4j7 nfl jlu 00y s3 3k 3y9 5u ya 6mq h2 mf ig1 54r tpe 2s jdt un 5g0 5z l09 f4w 3ua sz f9 7i cn1 xht qvb 4pk ms l74 n5 z8 f9 hyr nxz fd ct kyn w7 snz k5y jg ytf gm zzq 7i 8lz 49 3cn e59 s5 74e q3 3j 4h kt x6 kv lk y6o 26 3r gq 07 3i 42 yml m2k qus pbs c1 i5 1t tgj 2j y3 tj 3t pr 0d icb utv 9a qb 37i m1s 73b 03 l3 i36 z0 ze slp c4r ts9 1ob y2a ehf gvl 9h4 5fb bv je p7w mo lw 1ru dzx pof gu0 9oo eq4 yu1 83 su3 x1 ccv a5 vkm 0a fr8 ovo r2c tw oq le ts 9e9 j0o olc w97 bnl 46 7y3 ys 1ij lt7 pf rt tv es5 q4 acv fs9 yj 7w gkg ey om ry j1 lfe fw n04 aa2 cw se 7w pl yu j2y 9d gb szr b9 fml 607 vpx vt pq3 3lp lqo 2ch sp 5c vn 

FDA authorizes Pfizer’s Paxlovid, the first antiviral pill to treat COVID-19

Canadian approval not likely before end of year

Alexander Tin – CBS News

The U.S. Food and Drug Administration announced Wednesday it has greenlighted Pfizer’s antiviral pills to treat COVID-19 for emergency use, allowing limited use of the drug in Americans as young as 12 who are at “high risk for progression to severe COVID-19.”

The new treatment option comes as doctors are facing a nationwide shortage of monoclonal antibodies to treat high-risk cases of the disease, with most formulas ineffective against the fast-spreading Omicron variant. 

Early data suggests Pfizer’s pills, called Paxlovid, are effective against Omicron cases. The drugmaker says it works to block the ability of the virus to make copies of itself.

“This authorization provides a new tool to combat COVID-19 at a crucial time in the pandemic as new variants emerge and promises to make antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19,” the FDA’s Dr. Patrizia Cavazzoni said in a statement on Wednesday. 

Pfizer first sought emergency use authorization for Paxlovid in November. The company said it was shown in clinical trials to cut the chances of hospitalization or death by 88% among adults at high-risk of severe COVID-19, compared to a placebo. 

Pfizer is also running clinical trials to gather data on its use in two other potential groups of patients: for treating cases in people at “standard risk,” as well as for preventing disease in people who are household contacts of a COVID patient. If it proves safe and effective in those uses, the drugmaker could seek wider authorization from the FDA.

Paxlovid treatment needs to begin within a few days of first developing symptoms. A course of treatment is made up of three tablets that are taken twice a day, in the morning and evening, over the course of five days, for a total of 30 pills. Two of the tablets are nirmatrelvir, an antiviral Pfizer designed to target SARS-CoV-2, and one is ritonavir, a drug that has also been used to treat HIV.

Like with some other COVID-19 treatments that have been authorized by the FDA, the regulator will limit Pfizer’s drug to only people at “higher risk of being hospitalized for COVID-19.” That includes seniors and people with underlying conditions like heart disease or diabetes. 

Distribution of the drug will be controlled by the Biden administration, which purchased 10 million courses of the drug in November. 

A request to authorize another antiviral pill called molnupiravir, developed by Merck and Ridgeback Biotherapeutics, has also been pending for months before the FDA, after the agency’s outside advisers questioned its lower-than-expected effectiveness and concerns over risks associated with the drug.

Pfizer’s pill did not go before the FDA’s Antimicrobial Drugs Advisory Committee. The company’s executives have argued that the risks associated with their antiviral were lower than molnupiravir, more comparable to widely-used monoclonal antibody treatments that have already been greenlighted by the regulator. 

Potential risks and side effects

The FDA said Wednesday it was continuing to evaluate the safety and effectiveness of Paxlovid, and warned it should not be taken with some other drugs or by people with untreated HIV-1 infection. 

Loss of taste was the most commonly reported side effect of the drug in trials, occurring in 6% of recipients compared to less than 1% of placebo recipients. Slightly more recipients of Paxlovid also had diarrhea, high blood pressure, and muscle aches.

The promising results seen with Pfizer’s trial were among people who began taking the drug within the first days after they were diagnosed, early in the course of their disease. 

“Paxlovid is available by prescription only and should be initiated as soon as possible after a diagnosis of COVID-19 and within five days of symptom onset,” the FDA said. 

That could pose a challenge for many Americans who are now facing long waits for COVID-19 tests, even if they seek out testing immediately after they first feel symptoms.

“Our patient journey market research shows that symptomatic patients may wait up to three days before getting tested. From there, to take another one to three days for the patient to be tested and then another one to two days to be diagnosed,” Pfizer’s Angela Lukin told investors earlier this month. 

Pfizer says it is ready to begin deliveries of Paxlovid in the U.S. immediately, supplying up to 10 million courses of the treatment through next year. However, only thousands — not millions — of courses of the drug are expected to be available this month, Bourla told The Wall Street Journal earlier this year

“This breakthrough therapy, which has been shown to significantly reduce hospitalizations and deaths and can be taken at home, will change the way we treat COVID-19, and hopefully help reduce some of the significant pressures facing our healthcare and hospital system,” Pfizer’s CEO Albert Bourla said in a release.